01678nas a2200373   4500000000100000008004100001260001300042653001000055653000900065653001100074653003300085653001100118653001100129653003000140653002100170653002500191653000900216653001600225653002500241653000900266653001700275100001500292700001600307700001300323700001500336700001400351700001400365700001400379245009700393300001000490490000700500520078300507022001401290       1992                            d  c1992 Nov10aAdult10aAged10aBiopsy10aDrug Administration Schedule10aFemale10aHumans10aInjections, Intralesional10aInterferon-gamma10aLeprosy, lepromatous10aMale10aMiddle Aged10aRecombinant Proteins10aSkin10aTime Factors1 aBottasso O1 aBesuschio S1 aMerlin V1 aMorini J C1 aBernabo J1 aFalcoff R1 aFalcoff E00aLepromatous leprosy treated with recombinant interferon gamma: cutaneous histologic changes.  a813-70 v313 a<p>We report on the histologic changes occurring in single cutaneous lesions, from six active lepromatous patients, 1 week following the administration of three daily intradermal injections, 35 micrograms each, of recombinant interferon gamma (rIFN-gamma). Except for a strong induration at the injection site, rIFN-gamma produced no adverse systemic reactions and was able to promote a remarkable influx of T-lymphocytes, mononuclear phagocytes with large nuclei, nonvacuolated cytoplasm, and reduced lysozyme reactivity. Furthermore, despite no clear-cut reduction of mycobacterial dermal burden, bacilli showed a clear increase in the granular appearance. Present findings provide a basis for further elucidation of rIFN-gamma as an additional tool for leprosy treatment.</p>  a0011-9059